Novo inks NLRP3 deal with Ventus Therapeutics

Sept. 29, 2022

Novo Nordisk has entered into an exclusive worldwide license agreement with Ventus Therapeutics to develop and commercialize candidates from Ventus’ portfolio of peripherally-restricted NLRP3 inhibitors.

Per the deal, Massachusetts-based Ventus will receive $70 million upfront, with potential additional milestones of up to $633 million, plus potential royalty payments and R&D funding. In exchange, Novo Nordisk will receive exclusive worldwide rights to develop and commercialize Ventus’ lead NLRP3 inhibitor program, VENT-01, for a broad range of diseases, including nonalcoholic steatohepatitis (NASH), chronic kidney disease and other cardiometabolic conditions.

Ventus will retain the rights to its VENT-02 program, through which it will continue to develop NLRP3 inhibitors for certain systemic diseases, including specific inflammatory and respiratory diseases. In addition, Ventus retains worldwide rights to the company’s distinct brain-penetrant NLRP3 inhibitor program.

Both the VENT-01 and VENT-02 programs are still in IND-enabling studies.

With the deal, Novo will join some big names pursuing the NLRP3 space, including Roche and Novartis.